Tolerability of adjuvant chemotherapy with S-1 after curative resection in patients with stage II/III gastric cancer
Tolerability of adjuvant chemotherapy with S-1 after curative resection in patients with stage II/III gastric cancer
复制标题
DOI：
10.3892/ol.2012.882
复制
发表时间：
2012-11-01
期刊：
影响因子：
2.9
通讯作者：
Hase, Kazuo
中科院分区：
文献类型：
--
作者：
Tsujimoto, Hironori;Horiguchi, Hiroyuki;Hase, Kazuo
日本临床肿瘤组试验的结果证明，S-1辅助化疗对II/III期胃癌有效，并建议将该疗法作为治愈性1）2胃切除术后的标准治疗。我们回顾了58例II/III期胃癌根治性1）2切除术后接受S-1辅助治疗的连续患者的治疗结局;根据患者体表面积确定使用的标准剂量。24例患者（41.3%）在12个月前停止治疗。与未完成S-I辅助治疗的患者相比，完成12个月S-I辅助治疗的患者更年轻，更频繁地接受高级医生（>15年经验）的治疗。然而，两组之间的病理特征和手术方式没有差异。完成12个月S-1辅助治疗的患者的总生存期和无复发生存期更好。疲劳和恶心与停止S-I治疗相关。总之，手术后立即出现疲劳和胃肠道症状，
The results of the Japan Clinical Oncology Group trial demonstrated that adjuvant chemotherapy with S-1 for stage II/III gastric cancer is effective and suggested that this therapy should be adopted as the standard treatment following curative 1)2 gastric dissection. We reviewed treatment outcomes in 58 consecutive patients who received adjuvant therapy with S-1 for stage II/III gastric cancer following curative 1)2 dissection; the standard dosage used was determined on the basis of the patient body surface area. Twenty-four patients (41.3%) discontinued treatment before 12 months. Patients who completed 12 months of adjuvant therapy with S-I were younger and more frequently treated by senior doctors (>15 years of experience) than those who did not. However, no differences existed in pathological features and surgical procedures between groups. Overall survival and relapse-free survival were better in patients who completed 12 months of adjuvant therapy with S-1. Fatigue and nausea were associated with discontinuation of S-I treatment. In conclusion, immediately after surgery, fatigue and gastrointestinal symptoms of